New Gut Microbiome Research Targets Portal Hypertension Dr David Johnson explores recent data with urolithin A, a gut metabolite that’s shown early promise in studies with portal hypertension.
The Pittsburgh-based company owns treatment centers across the U.S. STORY HIGHLIGHTS: David Johnson brings 25 years of behavioral health experience to his new role leading Aliya Health Group.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback